Essex Partners Completes Acquisition of ScarMD and Hematix for Platform Company SkinGenuity

Essex Partners, LLC, an independent sponsor and affiliate of Essex Capital Group, Inc., announced that it recently closed an add-on acquisition of a skincare product line that includes established, best-in-class scar (ScarMD) and bruise (Hematix) treatments. The acquisition will further diversify the product offering for Essex’s existing platform company, SkinGenuity, LLC.

SkinGenuity has developed leading-edge skincare products that use a combination of bio-engineered growth factors and DNA enzymes to repair and rejuvenate multiple skin issues. Its products are currently sold through a global distribution network.

Paul Guilbaud, SkinGenuity CEO commented, “Adding these scar and bruise treatments to our product mix complements our existing offering while expanding our distribution network into China and South Korea, where these new products are already commercialized. We believe this acquisition gives us a compelling opportunity to grow the scar and bruise revenues through our current global network as well as accelerate SkinGenuity’s sales of existing products in China and South Korea.”

This acquisition marks the third independent sponsor transaction closed by Essex Partners in 2023. Terms of the transaction were not disclosed.

Contact Information

Rob Swain

President

Oxford + Bond

Contact via E-mail